Dyne Therapeutics Crescita futura

Criteri Future verificati 0/6

Dyne Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 37.7% e 59.9% all'anno. Si prevede che l'EPS crescerà di 39.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -127.6% in 3 anni.

Informazioni chiave

37.7%

Tasso di crescita degli utili

39.71%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	23.2%
Tasso di crescita dei ricavi	59.9%
Rendimento futuro del capitale proprio	-127.58%
Copertura analitica	Good
Ultimo aggiornamento	22 Dec 2025

Aggiornamenti recenti sulla crescita futura

Recent updates

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Jun 17

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Feb 28

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:DYN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	367	-316	-413	-380	7
12/31/2027	80	-454	-477	-434	9
12/31/2026	N/A	-498	-495	-457	13
12/31/2025	N/A	-447	-409	-382	13
9/30/2025	N/A	-424	-397	-376	N/A
6/30/2025	N/A	-413	-362	-360	N/A
3/31/2025	N/A	-367	-323	-320	N/A
12/31/2024	N/A	-317	-295	-292	N/A
9/30/2024	N/A	-295	-244	-243	N/A
6/30/2024	N/A	-258	-220	-219	N/A
3/31/2024	N/A	-257	-220	-220	N/A
12/31/2023	N/A	-236	-189	-188	N/A
9/30/2023	N/A	-208	-184	-182	N/A
6/30/2023	N/A	-189	-176	-175	N/A
3/31/2023	N/A	-177	-152	-150	N/A
12/31/2022	N/A	-168	-157	-154	N/A
9/30/2022	N/A	-181	-157	-153	N/A
6/30/2022	N/A	-182	-141	-137	N/A
3/31/2022	N/A	-160	-157	-152	N/A
12/31/2021	N/A	-149	-123	-120	N/A
9/30/2021	N/A	-126	-114	-112	N/A
6/30/2021	N/A	-97	-98	-96	N/A
3/31/2021	N/A	-77	-59	-58	N/A
12/31/2020	N/A	-59	-48	-47	N/A
9/30/2020	N/A	-36	-32	-30	N/A
6/30/2020	N/A	-28	-23	-22	N/A
3/31/2020	N/A	-21	-18	-17	N/A
12/31/2019	N/A	-15	-13	-12	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che DYN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che DYN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che DYN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che DYN non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che DYN non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che DYN non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/12/31 11:42
Prezzo dell'azione a fine giornata	2025/12/30 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Dyne Therapeutics, Inc. è coperta da 24 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Brian Skorney	Baird
William Pickering	Bernstein
Keay Nakae	Chardan Capital Markets, LLC

Dyne Therapeutics Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 10% to US$39.00

Price target decreased by 8.3% to US$36.32

Price target decreased by 8.4% to US$40.35

Price target increased by 8.9% to US$50.00

Price target increased by 8.3% to US$37.56

Price target increased by 9.6% to US$28.50

Recent updates

Dyne Therapeutics, Inc. Announces the Appointment of Vikram Karnani to Its Board of Directors

Price target increased by 10% to US$39.00

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350.000014 million.

Dyne Therapeutics, Inc. Announces Topline Results from Registrational Expansion Cohort of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Insufficient new directors

Dyne Therapeutics, Inc. Appoints Brian Posner to Its Board of Directors

Dyne Therapeutics, Inc. Announces Fda Breakthrough Therapy Designation for Dyne-251 in Duchenne Muscular Dystrophy (Dmd)

Price target decreased by 8.3% to US$36.32

CEO, President & Director recently bought US$911k worth of stock

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000006 million.

Price target decreased by 8.4% to US$40.35

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Dyne Therapeutics, Inc., Annual General Meeting, May 30, 2025

Dyne Therapeutics, Inc. Announces New Long-Term Clinical Data from Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

New major risk - Shareholder dilution

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics to Present Data from the Ongoing DELIVER Clinical Trial in Duchenne Muscular Dystrophy At Upcoming Presentations At the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics: Moving Forward On 2 Key Fronts

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

New minor risk - Share price stability

Dyne Therapeutics, Inc. Announces New Clinical Data from Its Ongoing Phase 1/2 Achieve Trial of Dyne-10 in Patients with Myotonic Dystrophy Type 1 (DM1)

New minor risk - Insider selling

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member